IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (Canceled)

2. (Previously presented) The method of claim 9, wherein the concentration of rotigotine in the composition is at least 0.5 mg/ml.

3. (Previously presented) The method of claim 9, wherein the concentration of rotigotine in the composition is 0.5 to 3 mg/ml.

4. (Previously presented) The method of claim 9, wherein the at least one chloride salt is selected from NaCl, triethylammonium chloride and tributylammonium chloride.

5. (Currently amended) A method for **[[the]]** treatment of Parkinson's disease comprising applying an iontophoretic device, which comprises a composition comprising **(a)** rotigotine **in a concentration sufficient to provide a therapeutically effective rotigotine flux for treatment of Parkinson's disease,** and **(b)** at least one chloride salt selected from the group consisting of triethylammonium chloride, tributylammonium chloride and combinations thereof in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5, onto **[[the]]** skin of a patient in need thereof.

6. (Previously presented) The method of claim 9, wherein the concentration of the chloride salt is 60 to 80 mmol/l.

7. (Previously presented) The method of claim 9, wherein the composition forms a donor phase of the iontophoretic device.

8. (Canceled)

9. (Currently amended) A method for **[[the]]** treatment of Parkinson's disease comprising applying an iontophoretic device, which comprises a composition comprising **(a)** rotigotine **in a concentration sufficient to provide a therapeutically effective rotigotine flux for treatment of Parkinson's disease,** and **(b)** at least one **pharmaceutically acceptable** chloride salt in a concentration of 1 to 140 mmol/l, the

composition having a pH of 4 to 6.5, onto **[[the]]** skin of a patient in need thereof.

10–15. (Canceled)

16. (Previously presented) The method of Claim 20, wherein the composition forming the donor phase of the iontophoretic device comprises rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, and wherein the pH of the donor phase is 4.5 to 5.5.

17. (Previously presented) The method of claim 5, wherein the concentration of rotigotine in the composition is at least 0.5 mg/ml.

18. (Previously presented) The method of claim 5, wherein the concentration of rotigotine in the composition is 0.5 to 3 mg/ml.

19. (Previously presented) The method of claim 5, wherein the concentration of the chloride salt is 60 to 80 mmol/l.

20. (Previously presented) The method of claim 5, wherein the composition forms a donor phase of the iontophoretic device.